NSE filing, NSE: INVICTA. Summary written from the filing by ALFA Finder's alert engine.
Invicta Diagnostic Ltd: key numbers
- Share price
- ₹74.50
- Market cap
- ₹93.66 Cr
- Revenue (annual)
- ₹32.35 Cr
- Net profit (annual)
- ₹4.91 Cr
- P/E (TTM)
- 19.1×Sector 54.5×
- Promoter holding
- 66.70%
- FII holding
- 1.54%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Invicta Diagnostic Ltd
All →Invicta Diagnostic Management Change
Invicta Diagnostic Limited reported changes to its leadership and audit team, including a director's re-appointment, a designation change, and a new secretarial auditor.
Invicta Diagnostic Annual General Meeting
Invicta Diagnostic Limited conducted its 3rd Annual General Meeting on September 19, 2026. The proceedings detailed company operations and future financial targets.
Invicta Diagnostic Board Meeting Outcome
Board approved business outlook and forward-looking guidance for the 3rd AGM on 19 September 2026. Company targets consolidated revenue of ₹45–50 crore with ~25% EBITDA margin.
Invicta Diagnostic Capacity Expansion
Invicta's subsidiaries commenced operations at two diagnostic centres in Shegaon and Pune. Investment is Rs. 70 lakhs for CT scan and pathology services.
- diagnostic service centres
- 2 centres
Invicta Diagnostic Annual General Meeting
Invicta Diagnostic approved the notice for its 3rd Annual General Meeting scheduled for 19th September 2026, alongside adoption of financial reports and director appointments.
Invicta Diagnostic Merger & Restructuring Worth ₹0.01 Cr
Invicta Diagnostic Limited is selling its associate entity, MSCRIBEIT INFOTECH LLP, for a cash consideration of Rs. 50,000. The transaction is expected to conclude by March 2027.
- Value
- ₹0.01 Cr
Other product launch announcements
All →LTM Product Launch
LTM publishes AI-QEM, its Quantum Error Mitigation tool, in IBM's Quantum Functions Catalog, becoming the first global systems integrator to do so.
Jeena Sikho Lifecare Product Launch
Jeena Sikho Lifecare launched ten new Ayurvedic healthcare products in the domestic market on November 11, 2026. The filing gives product-wise details under SEBI product-launch disclosure rules.
HCL Technologies Product Launch
HCLTech launched a pre-configured semiconductor PLM solution built on PTC Windchill, developed in collaboration with PTC. The release states no contract value or deal size, and the launch is a new product offering.
Morepen Laboratories Product Launch
Morepen launched Desloratadine Tablets USP 5 mg, its first US prescription generic, through subsidiary Morepen Bio Inc. It also filed a Sitagliptin ANDA with the US FDA.
AstraZeneca Pharma India Product Launch
AstraZeneca Pharma India will launch Datverzo, Datopotamab Deruxtecan, in India in November 2026. The drug holds DCGI import and market permission for HR-positive, HER2-negative breast cancer.
Raama Finance Product Launch
Raama Finance launched 'Rupya Lelo', a digital lending platform offering instant personal loans, on October 6, 2026. The product is available only in India, and no loan amount or financial figure is disclosed.